Omilon AS

Based in Norway, Omilon AS specializes in AI-driven solutions that enhance clinical documentation in healthcare settings, streamlining patient interactions and improving efficiency for healthcare professionals. Omilon AS, founded in 2020 and headquartered in Oslo, Norway, focuses on providing innovative documentation solutions for healthcare. The company has completed 1 deal, with its most recent deal occurring on March 13, 2026. The founder's background details are not provided, and there are no mentions of any pivots in business strategy or subsidiaries.

Omilon specializes in AI-driven solutions designed to enhance clinical documentation within healthcare settings. Their core products include "Tandem," an AI-based conversational solution that transforms patient interactions into structured notes in real-time, significantly improving the documentation process for healthcare professionals. This product allows users to focus on patient care rather than administrative tasks, as it listens to consultations and generates summaries automatically, thereby optimizing workflow and improving efficiency. The company also offers speech recognition technology that enables healthcare providers to dictate notes rapidly, updating patient records as they speak.

Omilon’s solutions are employed by a diverse client base, which includes public and private hospitals, specialist clinics, and general practitioners across various geographical markets, including Norway and other European regions. Omilon's revenue model is primarily structured around B2B transactions, where healthcare institutions subscribe to their services on a contractual basis. Clients typically engage with the company through partnerships or direct agreements for using their flagship products, such as Tandem and specialized speech recognition software. These arrangements may involve recurring subscription fees, which are determined based on the scale of implementation and the number of users within the institution.

The pricing plans are designed to cater to different organizational needs, ensuring that both small practices and larger healthcare systems can effectively leverage their technology for improved patient documentation. The emphasis on long-term partnerships suggests a steady revenue stream as clients experience the value of improved efficiency and time savings through these solutions. In March 2026, Nexus AG, a portfolio company of TA Associates and Luxempart, agreed to acquire Omilon AS. The financial terms of the acquisition were not disclosed.

This acquisition enables Nexus AG to gain integration technology that supports the rollout of responsible artificial intelligence across healthcare documentation systems.